These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23327578)

  • 1. Pharmacogenetics of clinical response to risperidone.
    Llerena A; Berecz R; Peñas-Lledó E; Süveges A; Fariñas H
    Pharmacogenomics; 2013 Jan; 14(2):177-94. PubMed ID: 23327578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.
    Correia CT; Almeida JP; Santos PE; Sequeira AF; Marques CE; Miguel TS; Abreu RL; Oliveira GG; Vicente AM
    Pharmacogenomics J; 2010 Oct; 10(5):418-30. PubMed ID: 19997080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
    Choong E; Polari A; Kamdem RH; Gervasoni N; Spisla C; Jaquenoud Sirot E; Bickel GG; Bondolfi G; Conus P; Eap CB
    J Clin Psychopharmacol; 2013 Jun; 33(3):289-98. PubMed ID: 23609392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
    Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
    Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
    Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
    Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes.
    Mas S; Gassò P; Alvarez S; Parellada E; Bernardo M; Lafuente A
    Pharmacogenomics J; 2012 Jun; 12(3):255-9. PubMed ID: 21173786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
    Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
    Kneller LA; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
    Ma L; Xiang Q; Zhao N; Hu C; Fang M; Tan Y; Chen S; Wang Z; Liu P; Sun K; Li Y; Wu F; Tian H; Fang M; Zhao X; Wang G; Cui Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110241. PubMed ID: 33400943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone-related weight gain: genetic and nongenetic predictors.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
    J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
    Vandenberghe F; Guidi M; Choong E; von Gunten A; Conus P; Csajka C; Eap CB
    Clin Pharmacokinet; 2015 Dec; 54(12):1259-72. PubMed ID: 26129906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A; Dorado P; Peñas-Lledó EM
    Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics and antipsychotic treatment response.
    Naumovska Z; Nestorovska AK; Filipce A; Sterjev Z; Brezovska K; Dimovski A; Suturkova LJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):53-67. PubMed ID: 26076775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
    Bork JA; Rogers T; Wedlund PJ; de Leon J
    J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinician experiences of employing the AmpliChip® CYP450 test in routine psychiatric practice.
    Dunbar L; Butler R; Wheeler A; Pulford J; Miles W; Sheridan J
    J Psychopharmacol; 2012 Mar; 26(3):390-7. PubMed ID: 19942639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia.
    Suzuki Y; Tsuneyama N; Fukui N; Sugai T; Watanabe J; Ono S; Saito M; Someya T
    J Clin Psychopharmacol; 2013 Jun; 33(3):411-4. PubMed ID: 23609388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment.
    Bozina N; Jovanović N; Lovrić M; Medved V
    Ther Drug Monit; 2008 Dec; 30(6):748-51. PubMed ID: 18806696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
    Roke Y; van Harten PN; Franke B; Galesloot TE; Boot AM; Buitelaar JK
    Pharmacogenet Genomics; 2013 Sep; 23(9):487-93. PubMed ID: 23851570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.